IQVIA Holdings Inc. (IQV) News
Track canonical SquawkNews coverage tagged to IQV, IQVIA Holdings Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 32 indexed stories across 16 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
IQVIA Holdings Price Target Announced at $345.00/Share by UBS
Ratings actions from Benzinga
NEWS | Sep 30, 2026, 12:29 PM UTC
L
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-q
EARNINGS | Sep 29, 2026, 08:15 PM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
L
IQVIA Holdings Is Maintained at Outperform by RBC Capital
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 12:44 PM UTC
L
RBC Capital maintains Outperform rating on IQVIA Holdings, $319 price target
RBC Capital maintained their Outperform rating on IQVIA Holdings's stock with a price target of $319.00.The price target implies an upside of 17.7% from the Sep 28 close of $270.97.Key takeaways from the analyst noteStro
EQUITY | Sep 29, 2026, 12:36 PM UTC
L
IQVIA Holdings Price Target Raised to $329.00/Share From $300.00 by Truist Securities
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 03:23 PM UTC
L
Truist Securities reiterates Buy rating on IQVIA Holdings, $329 price target
Truist Securities reiterated their Buy rating on IQVIA Holdings's stock with a price target of $329.00.The price target implies an upside of 21.7% from the Sep 25 close of $270.37.Key takeaways from the analyst noteStron
EARNINGS | Sep 28, 2026, 03:13 PM UTC
L
IQVIA Raises $2.0 Billion in 6.375% Senior Notes Due 2034 to Refinance Debt
IQVIA entered into an Indenture as its subsidiary issued $2.0 billion of 6.375% senior unsecured notes due 2034. Interest is payable semi-annually on March 15 and September 15, beginning March 15, 2027. Net proceeds will
NEWS | Sep 23, 2026, 09:15 PM UTC
M
IQVIA prices $2B senior notes due 2034
IQVIA priced an offering of $2B in aggregate principal amount of senior notes due 2034. The proceeds will be used to redeem in full the Senior 5.000% Notes due 2026 and to repay a portion of related debt.
RATES | Sep 09, 2026, 09:31 PM UTC
M
IQVIA prices $2.0 billion of 2034 senior notes at 6.375%
IQVIA intends to raise $2.0 billion through senior notes due 2034 priced at 6.375%. The proceeds are intended to refinance near-term debt.
EQUITY | Sep 09, 2026, 09:24 PM UTC
L
IQVIA prices senior notes
RATES | Sep 09, 2026, 09:15 PM UTC
M
IQVIA prices $2,000,000,000 of senior notes due 2034
IQVIA Holdings’ wholly owned subsidiary, IQVIA Inc., priced an offering of $2,000,000,000 aggregate principal amount of senior notes due 2034. Proceeds will be used to redeem in full the existing notes, as described in t
RATES | Sep 09, 2026, 09:13 PM UTC
L
IQV - IQVIA Announces Offering of Senior Notes
IQV - IQVIA Announces Offering of Senior Notes
RATES | Sep 09, 2026, 12:20 PM UTC
L
IQV - IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster - Click For
IQV - IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
EQUITY | Sep 03, 2026, 08:18 PM UTC
L
IQVIA announces AI-powered Predictive Clinical Development for sponsors
IQVIA said it has launched IQVIA Predictive Clinical Development, an AI-powered approach aimed at reducing avoidable delays and helping sponsors bring new therapies to patients faster.
EQUITY | Sep 03, 2026, 08:15 PM UTC
L
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
EQUITY | Aug 27, 2026, 08:25 PM UTC
L
IQVIA AI clinical decision support tool wins 2026 award
IQVIA says its AI-enabled clinical decision support tool won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.
EQUITY | Aug 20, 2026, 08:19 PM UTC
L
IQVIA ranks No. 1 pharmaceutical technology provider
IQVIA (IQV) is ranked No. 1 as a pharmaceutical technology provider by Everest Group, per the TradeXchange Newsdesk alert.
REGULATION | Aug 17, 2026, 08:21 PM UTC
M
IQVIA Partners With Medera
IQVIA partners with Medera for cardiac gene therapy
EQUITY | Aug 04, 2026, 08:18 PM UTC
H
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE: SHW ) rose sharply after the company reported better-than-expected second-quarter financial resu
EARNINGS | Jul 28, 2026, 02:05 PM UTC
L
IQV +11% after Co forecasts 2026 revenue, profit above estimates
IQV +11% after Co forecasts 2026 revenue, profit above estimates
EQUITY | Jul 28, 2026, 01:32 PM UTC
H
IQV shares +10% premarket after results and guidance as raises FY2026 adj EPS forecast to $12.80-$13.00 from prior forecast of $12.65-$12.95
IQV shares +10% premarket after results and guidance as raises FY2026 adj EPS forecast to $12.80-$13.00 from prior forecast of $12.65-$12.95as midpoint tops ests $12.90; posted Q2 EPS and rev beat $4.37B vs. est. $4.3B -
EARNINGS | Jul 28, 2026, 12:48 PM UTC
H
Iqvia sees FY26 adjusted EPS $12.80-$13.00, consensus $12.80
Iqvia sees FY26 adjusted EPS $12.80-$13.00, consensus $12.80
EARNINGS | Jul 28, 2026, 11:12 AM UTC
H
Iqvia reports Q2 EPS $3.15, consensus $3.03
Reports Q2 revenue...
EARNINGS | Jul 28, 2026, 11:11 AM UTC
H
IQVIA Holdings Raises FY2026 Adj EPS Guidance from $12.65-$12.95 to $12.80-$13.00 vs $12.80 Est; Raises FY2026 Sales Guidance from $17.150B
IQVIA Holdings (NYSE: IQV ) raises FY2026 Adj EPS guidance from $12.65-$12.95 to $12.80-$13.00 vs $12.80 analyst estimate. Raises FY2026 sales outlook from $17.150 billion-$17.350 billion to $17.275 billion-$17.475 billi
EARNINGS | Jul 28, 2026, 11:01 AM UTC
H
IQV IQVIA RESULTS: Q2, Q2 REV $4.368B vs. EST $4.301B, Q2 ADJ EPS $3.15 vs. EST $3.03, Q2 EPS $1.53, IQVIA Earnings Notes:, Outlook FY ADJ E
IQV IQVIA RESULTS: Q2, Q2 REV $4.368B vs. EST $4.301B, Q2 ADJ EPS $3.15 vs. EST $3.03, Q2 EPS $1.53, IQVIA Earnings Notes:, Outlook FY ADJ EPS $12.8-13 vs. EST $12.8, Outlook FY REV $17,275-17.475B vs. EST $17.286B
EARNINGS | Jul 28, 2026, 11:01 AM UTC
L
Implied EPS movers for tomorrow AM: KO +/-2.8%, GLW +/-10.6%, BA +/-4.7%, SHW +/-6.1%, SPGI +/-4.5%, HLT +/-3.6%, PCAR +/-6.5%, RCL +/-7.3%,
Implied EPS movers for tomorrow AM: KO +/-2.8%, GLW +/-10.6%, BA +/-4.7%, SHW +/-6.1%, SPGI +/-4.5%, HLT +/-3.6%, PCAR +/-6.5%, RCL +/-7.3%, UPS +/-5.6%, AMT +/-5.9%, ITW +/-5.3%, CARR +/-5.5%, ECL +/-6.0%, CNC +/-8.1%,
EQUITY | Jul 27, 2026, 05:42 PM UTC
L
Largest discount to VWAP QS (-6.31%) ACI (-5.23%) MEDP (-4.53%) MOH (-4.13%) RGEN (-3.89%) LITE (-3.46%) IQV (-3.41%) AUR (-3.37%) CMCSA (-3
Largest discount to VWAP QS (-6.31%) ACI (-5.23%) MEDP (-4.53%) MOH (-4.13%) RGEN (-3.89%) LITE (-3.46%) IQV (-3.41%) AUR (-3.37%) CMCSA (-3.3%) HUBS (-3.25%) (Russell 1000 names)
EQUITY | Jul 23, 2026, 03:42 PM UTC
H
Iqvia named short-term buy idea at Deutsche Bank
Deutsche Bank placed a "Catalyst call: Buy" on shares of Iqvia as a short-term investment idea. Iqvia has traded down 10% year-to-date and has underperformed peers despite 2026 guidance that the firm calls "in line-to-be
EARNINGS | Jul 09, 2026, 12:33 PM UTC
L
Iqvia price target raised to $240 from $210 at HSBC
HSBC analyst Sidharth Sahoo raised the firm's price target on Iqvia to $240 from $210 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's rel
EQUITY | Jul 06, 2026, 02:23 PM UTC
L
IQVIA shares are trading higher after Baird maintained its Outperform rating on the stock and raised its price target from $230 to $249.
IQVIA shares are trading higher after Baird maintained its Outperform rating on the stock and raised its price target from $230 to $249.
EQUITY | Jul 01, 2026, 02:18 PM UTC
L
Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $249
Baird analyst Eric Coldwell maintains IQVIA Holdings (NYSE: IQV ) with a Outperform and raises the price target from $230 to $249.
EQUITY | Jul 01, 2026, 11:02 AM UTC